Method Comparison of Intelligent Fingerprinting Drug Screening System

135 "donors" and nine "operators." "Operators" represent end users who utilize the screening system in an office or work setting. These subjects do not have to possess special training in laboratory methods. "Donors" represent end users either applying for employment or working at an organization that conducts pre-employment and/or periodic workplace drug screening.

Sufficient numbers of subjects will be screened to attain those numbers and to ensure that at least 33% of each sex and at least 15% Black subjects are included as "donors" in the study. At least two sites will have both sexes represented among "operator" subjects. Sites may recruit sufficient alternate subjects to ensure achievement of those numbers.

Subjects will be selected from members of the community at large.

Inclusion Criteria:

1. Able to provide informed consent 2. Completed the screening process within 30 days prior to dosing. 3. Healthy male and non-pregnant female subjects at the time of dosing. 4. Body mass index (BMI) from 18.0 kg/m2 to 32.0 kg/m2, inclusive 5. Weigh at least 60 kg. 5. Females of childbearing potential must be willing to practice an acceptable form of contraception, and have a negative urine pregnancy test on admission to the treatment phase of the study.

6. Males must agree to practice an acceptable form of contraception 7. Judged by the Investigator and/or designee to be in good health as documented by the medical history, and vital sign assessments.

Exclusion Criteria:

1. Unwilling or unable to provide informed consent.
2. More than three digits absent from the hands due to congenital or accidental cause(s).
3. Reports receiving any investigational drug within 30 days prior to dosing.
4. Reports a clinically significant illness during the 30 days prior to the in-clinic portion of the study (as determined by the Investigator).
5. Reports any personal history of substance abuse (including drug/alcohol abuse or addiction) or mental illness (e.g. major depression) within one year prior to screening visit.
6. Is pregnant (females only).
7. Presence of any clinically significant results from laboratory tests and vital signs assessments, as judged by the Investigator.
8. Reports history of respiratory depression (e.g., sleep apnea).
9. Reports history of reaction to codeine (e.g., nausea, allergy).
10. Current severe hypotension (i.e., systolic blood pressure <90 mmHg).
11. Reports known or suspected gastrointestinal obstruction including, paralytic ileus.
12. Reports current presence of acute bronchial asthma/ upper airway obstruction.
13. Reports a history of clinically significant allergies, including food or drug allergies, as judged by the Investigator.
14. Reports history or current condition of adrenal insufficiency.
15. Reports history or current condition of renal disease.
16. If, in the opinion of the Investigator, the subject is not suitable for the study.